November 2021

$9M Grant Funds Study of Gut-Brain Connection in Parkinson’s Disease

Dr. Michael Kaplitt, a professor of neurological surgery at Weill Cornell Medicine and a longtime leader in developing cutting-edge surgical therapies for movement disorders, leads a team that has been awarded a three-year, $8.9 million grant from the Aligning Science Across Parkinson’s (ASAP) initiative. The grant will fund an ambitious and innovative multi-institutional collaborative effort to study […]

$9M Grant Funds Study of Gut-Brain Connection in Parkinson’s Disease Read More »

CORE ONE LABS’ AKOME SEEKS TO REVOLUTIONIZE TREATMENT OF PARKINSON’S DISEASE AND SUBMITS APPLICATION TO PROTECT IP

Akome’s AKO004 psychedelic drug formulation, for use in the treatment of Parkinson’s disease, is a composition comprising the psychedelic compound N,N-dimethyltryptamine (DMT) and, a specifically chosen, naturally occurring plant bioactive.  Initial data analysis indicates that the AKO004 composition is safe and efficacious for use, and presents many positive properties which may counter or mitigate neurodegeneration

CORE ONE LABS’ AKOME SEEKS TO REVOLUTIONIZE TREATMENT OF PARKINSON’S DISEASE AND SUBMITS APPLICATION TO PROTECT IP Read More »

MISFOLDED α-SYN – FROM RELEASE AND UPTAKE TO CONTAGION OF ADJACENT CELL, ANY LINKS WITH GUT?

Alpha-synuclein(α-Syn) is an intracellular protein which is constantly synthesized and degraded underphysiological conditions. Abnormal aggregation of this protein within neuron is associated with severalneurodegenerative disorders, including Parkinson’s disease. Although the exact mechanism of initiation ofaggregation and misfolding pathway of a-Syn is yet to be discovered; it’s mechanism of spreading throughinterconnected neuronal networks has taken acompelling

MISFOLDED α-SYN – FROM RELEASE AND UPTAKE TO CONTAGION OF ADJACENT CELL, ANY LINKS WITH GUT? Read More »